What TitrateLab is, and how $1,000 in verified orders earns you lifetime access
TitrateLab is a vendor-intelligence platform and order-routing service built for people who are tired of the grey-market proxy model. This is the coming-soon note: what we're building, who it's for, and why our founding members get permanent access in exchange for $1,000 in verified orders.
Read the launch note →Have a Certificate of Analysis we don't?
Drop it here. Anonymous by design — no account, no email, your IP is hashed weekly for abuse-prevention only. We OCR it, parse it, and add it to the corpus that powers every vendor page on this site. The long tail (Telegram-only sellers, niche OEMs) only gets covered if customers with skin in the game contribute one.
Submit a COA →Browse by peptide
- Semaglutide · 691
- Insulin · 529
- Tirzepatide · 512
- Liraglutide · 303
- THYMOSIN-ALPHA-1 · 147
- Retatrutide · 134
- LL-37 · 117
- IGF-1 · 108
- Mots-c · 108
- BPC-157 · 107
- GHRP-6 · 105
- MK-677 · 95
- GHRP-2 · 92
- Ghk-cu · 91
- Sermorelin · 89
- SS-31 · 86
- Epitalon · 81
- Melanotan-ii · 80
- Mgf · 77
- Selank · 74
- Semax · 72
- Cagrilintide · 68
- PT-141 · 68
- Oxytocin · 56
- Hgh · 45
- Ipamorelin · 45
- Dulaglutide · 40
- Humanin · 37
- Survodutide · 37
- Tesamorelin · 36
-
The Peptide Vendor Graveyard: every verified shutdown, exit scam, and FDA action 2018-2026
A dated, cited archive of every major enforcement action, vendor shutdown, lab controversy, and regulatory milestone in the research peptide grey market from 2018 through April 2026. Primary sources only. Updated as events happen. This is the canonical reference for "what happened to that vendor" — so you stop relying on Reddit rumors and forum memory.
-
The July 23 PCAC review could collapse the peptide grey market's core demand. Here's what's at stake.
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee meets to review whether BPC-157, TB-500, and ~12 other peptides should be restored to Category 1, a move HHS Secretary RFK Jr. announced on JRE #2461 back in February. If approved, compounding pharmacies could legally dispense these compounds for the first time since September 2023, and the grey-market moat that built Peptide Sciences, Amino Asylum, and the rest collapses. What the community needs to know before the vote.
-
HGH is discussed 88× more than it's tested. Here's what the 70 batches we have show.
Across a 19-month window, HGH appeared in 6,172 peptide-tagged Discord messages in our corpus. Our Certificate-of-Analysis database contains 70 HGH assays, substantially more than earlier versions of this article after a MESO-Rx analytical-lab subforum crawl and Janoshik public-portal backfill. The 88× gap between how much people discuss it and how much anyone verifies it is still the largest testing gap of any compound we track. Here's what the 70 batches show, and why HGH remains the hardest compound on this market to actually verify.
-
The peptide grey market collapsed in 9 months. Quality got dramatically better at the same time.
Between June 2025 and March 2026 the research-peptide grey market lost its three biggest players: Amino Asylum to an FDA raid, Science.bio to voluntary closure, and Peptide Sciences to a regulatory reversal. We measured what happened to quality across 8,452 tested batches from 294 manufacturers, and the story nobody is telling is that purity went up.